DynPort Vaccine Co. and Baxter International have received a $201.2 million contract modification from the U.S. Department of Health and Human Services (HHS) for the development of Baxter’s cell-cultured seasonal and pandemic influenza candidate vaccines. The contract funds development of the seasonal influenza vaccine through FDA licensure, and the pandemic vaccine candidate through Phase II clinical trials in adults and pediatric Phase I clinical trials. DVC, the prime contractor for ...